Introduction
Our incomplete understanding of the mechanisms underlying chronic pain hypersensitivity accounts for the general ineffectiveness of currently available options for the treatment of chronic pain syndromes. Despite its complex pathophysiology, it is clear that many aspects of neuropathic pain are associated with short-term and longterm changes in the excitability of sensory neurons in the dorsal root ganglia (DRG). Neuromimmune interactions are increasingly recognized as important elements in nociceptive processing. Recent evidence suggests that the upregulated expression of inflammatory chemotactic cytokines (chemokines) in association with tissue damage or infection serve not only in the capacity of leukocyte chemotaxis but also in the generation of hyperexcitable sensory neurons. This review discusses the diverse changes produced by inflammatory chemokines in the context of disease-associated and injury-induced chronic pain syndromes.
A complex biological process that has largely been ignored by the field of pain research is the concept of persistent acute (or chronic) inflammation within the nervous system also known as neuroinflammation. For many years, the nervous system was considered to be 'immune privileged', neither susceptible to nor contributing to inflammation. It is now appreciated that the nervous system does indeed exhibit inflammatory processes in response to injury, infection, or disease. To date, many of the inflammatory processes that are studied in the nervous system are associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, prion diseases, multiple sclerosis, and HIVdementia. Additionally, the resident immune cells that secrete a variety of pro-inflammatory and neurotoxic factors are thought to induce and/or exacerbate neurodegeneration [1] . This state of neuroinflammation can also facilitate or directly produce pain by releasing cytokines, reactive oxygen intermediates, proteinases, and complement proteins, which lend themselves to recruitment of immune cells and activation of glial cells [2, 3] . Many of these events induce the expression of a family of factors known as chemotactic cytokines or chemokines. Chemokines function largely to orchestrate the migration of leukocytes to inflamed tissue. Injury or diseaseinduced de-novo chemokine/receptor expression within the nervous system, however, is also linked to glial activation states and neuronal hyperexcitability and recently has been implicated in the development and persistence of many pathologic pain states [4 ] .
Chemokines, chemokine receptors, and intracellular signaling
Chemokines constitute a large family of relatively low molecular weight proteins classified by the presence of a cysteine motif in the N-terminal region of the protein.
Initial characterization of chemokines divided the family into a-chemokines and b-chemokines. In a-chemokines, one amino acid separates the first two cysteine residues (cysteine-X amino acid-cysteine or CXC), whereas in b-chemokines the first two cysteine residues are adjacent to each other (cysteine-cysteine, or CC). Two additional classes were added for the chemokines, lympotactin (single cysteine, XC) and fractalkine (first two cysteines are separated by three amino acids, CX3C). The chemokine nomenclature herein utilizes both the original ligand name and the systematic name. The systematic name uses XC, CC, CXC and CX3C, indicating the class to which the chemokine belongs, followed by the letter 'L' (for ligand) and then a number. The numbering system corresponds to that already in use to designate the genes encoding each chemokine (see Table 1 ).
All chemokines exert their biological effects through the activation of an extended family of seven transmembrane G-protein-coupled receptors (GPCRs). Nineteen chemokine receptors have been cloned including seven CXC receptors (CXCR1-7), 10 CC receptors (from CCR1 to 10), lymphotactin (XCR1), and fractalkine (CX3CR1). Chemokine receptors are notoriously promiscuous, that is single chemokines can activate several different chemokine receptors (see Table 1 ). There are, however, instances when a chemokine receptor is activated by a single chemokine. For example, the CXCR4 receptor has only one known ligand, stromal-derived factor-1 alpha (SDF1a/CXCL12) (also see [5] ).
A common response of all nonexcitable cells to chemokine stimulation is chemotaxis. However, the presence of 
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chemokine receptors on neurons often triggers downstream signaling cascades via dissociation of G proteins that induce the phosphoinositide 3-kinase pathway (PI3K) or activates phospholipase C resulting in Ca 2þ influx and protein kinase C activation [6] . Knockout experiments in mice have revealed the central role played by PI3K in cellular responses to chemokines [7, 8] , whereas transient Ca 2þ elevations are one of the most well characterized effects of chemokines [9, 10] . It is important to note that most responses to chemokines are blocked with pertussis toxin, indicating that many chemokine receptors are G i/o coupled. Recent functional characterizations of chemokine receptors suggest these proteins form dimers that could further regulate their signaling [11, 12] . In addition, evidence also suggests that chemokines may activate mitogen-activated protein kinase (MAPK) by either G a or G-protein-independent signaling [11, 13] .
Although chemokines usually have a beneficial effect in limiting responses to cellular and organ damage, a breakdown in the regulation of the inflammatory response may result in a wide range of chronic diseases. This chemokine-mediated component is also likely to extend to the pathogenesis and maintenance of chronic pain both in disease-related conditions (e.g. multiple sclerosis, HIV-1, and herpes simplex virus) and following trauma, all of which are associated with innate immune responses and prolonged expression of chemokines and their receptors by the cellular elements of the nervous system [4 ] . As such, interference with chemokine function is a promising approach for the development of novel antiinflammatory medications for both disease and chronic pain conditions.
Chemokines/receptors in acute and chronic pain
Tissue damage, inflammation or injury of the nervous system may result in chronic neuropathic pain characterized by hyperalgesia (increased sensitivity to painful stimuli), allodynia (innocuous stimuli perceived as painful) and spontaneous pain. Immune and nonimmune cells associated with the injury response release pro-inflammatory mediators such as prostaglandins, histamine, serotonin, protons, bradykinin, nerve growth factor, and pro-inflammatory cytokines that can sensitize primary afferent neurons and contribute to pain hypersensitivity. There is also adequate evidence demonstrating that, like other inflammatory mediators, chemokines can elicit hypernociception. For example, Oh et al. [9] demonstrated that the simple injection of SDF1a/CXCL12, Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES/CCL5) or macrophage inflammatory protein-1a (MIP-1a/CCL3) into the un-inflamed adult rat hind paw produces dose-dependent tactile allodynia. These behavioral experiments in combination with accompanying reverse transcriptase-PCR, calcium imaging studies and immunohistochemistry confirmed the presence and functionality of the respective chemokine receptors, CXCR4, CCR5 and CCR4 in rodent DRG sensory neurons. Similar behavioral effects were observed following the introduction of interleukin-8 (IL-8/CXCL8) [14] and intrathecal introduction of fractalkine (CX3CL1) [15] .
Peripheral sensitization as influenced by chemokines may be due to receptor activation and downstream signaling and/or to a sensitization of transient receptor potential (TRP) cation channels such as the capsaicin-sensitive TRPV1 [16] or the mechanosensitive variant TRPA1 [17, 18] . For example, recent investigations revealed MIP-1a/CCL3 enhanced the response of TRPV1-positive neurons to capsaicin by inducing calcium influx and protein kinase C (PKC) activation [19] . The activation of both TRPV1 and TRPA1 by monocyte chemoattractant protein-1 (MCP-1/CCL2) signaling has also been observed in previously injured nociceptive DRG neurons [20 ] .
Functional expression of chemokines/receptors in the damaged nervous system may participate in both the cause and symptomology of diverse pathological pain states. To date the evidence in animal models includes the upregulation of chemokines/receptors in partial ligation of the sciatic nerve [21] [22] [23] 24 ], chronic constriction injury of the sciatic nerve [25] [26] [27] , chronic compression of the L 4 L 5 DRG (CCD; a rodent model of spinal stenosis) [28, 29] , spinal cord contusion [30] , chemically induced focal nerve demyelination [31 ,32] , bone cancer pain [33] , zymosan or adjuvant-induced inflammatory pain [34] [35] [36] [37] 38 ], and the chemotoxic effects of some anti-HIV therapeutics [39 ] . Despite the potential importance of these factors for clinical pain syndromes, only a few studies have been designed to investigate the presence of altered levels of chemokines. These include the measurement of chemokine levels in prostatic secretion from individuals diagnosed with chronic pelvic pain syndrome [40] , herniated lumbar intravertebral disk specimens [41] and the cerebral spinal fluid (CSF) taken from individuals diagnosed with chronic regional pain syndrome (CRPS) [42] [43] [44] . Although these studies did not reveal a specific molecule that could serve as a diagnostic marker of a chronic pain syndrome, it was notable that CSF from patients with CRPS did reveal a common pattern of elevated cytokines and chemokines in 11 of 22 individuals tested [43] .
Role of monocyte chemoattractant protein-1/ CCR2 in nociceptive signaling
Of the many chemokines induced by injury or disease, the chemokine receptor CCR2 and its preferred ligand MCP-1/CCL2 consistently appears to be of special importance in peripheral nerve and neuronal hyperexcitability. The importance of this chemokine/receptor pairing in neuropathic pain states was first demonstrated in CCR2 knockout mice. Testing of acute pain behavior in CCR2 knockout mice does not differ from wild-type mice. Following partial ligation of the sciatic nerve, a model known to induce hypernociception, CCR2 knockout mice failed to display mechanical hyperalgesia [21] , whereas overexpression of glial MCP-1 by transgenic mice produced enhanced nociceptive responses [45] . Confirmation of a de-novo role for MCP-1/CCR2 signaling in injured neurons was observed following chronic compression of the DRG (a model of spinal stenosis). In this investigation, the injury produced neuronal upregulation of both MCP-1 and CCR2 in the DRG, whereas exogenous administration of MCP-1/CCL2 produced a depolarized resting membrane potential and increased firing in the neuronal cell bodies [28] . Subsequent studies [31 ] demonstrated that not only did sensory neurons following peripheral nerve injury exhibit chronic upregulation of functional MCP-1/ CCR2 signaling in neurons but a CCR2-specific receptor antagonist could reverse hypernociceptive behavior in the injured animal. Further investigations into the excitatory effects of MCP-1/CCR2 signaling in sensory neurons have revealed that regulation of the CCR2 chemokine receptor expression in neurons is activity-dependent on the signal transcription factor, Nuclear Factor in Activated T cells (NFATs) [46 ] , and MCP-1 activates a noncation selective voltage-independent, depolarizing current and inhibited a voltage-dependent outward current [29] . Moreover, MCP-1 protein expression by DRG neurons following nerve injury is colocalized with calcitonin gene-related peptide in large dense core vesicles and release of MCP-1 vesicles could be induced from the soma by depolarization in a Ca 2þ -dependent manner [20 ] .
The role of MCP-1/CCR2 signaling is not limited to the DRG soma. Zhang and De Koninck [26] recently demonstrated that MCP-1/CCL2 is also present in central afferent fibers in the spinal cord. Electrical activity due to peripheral nerve injury may serve to stimulate central afferent release of MCP-1/CCL2 into the spinal cord dorsal horn activating CCR2 bearing glial cells or neurons [21,24 ,26] . Notably, neuronally derived chemokines that activate glial cells also include the chemokine fractalkine/ CX3CL1. Both endogenous and exogenous fractalkine/ CX3CL1 serve to activate microglial cells following peripheral nerve injury [25, 34] . Perhaps more importantly, CX3CR1 antagonists can both prevent and attenuate ongoing neuropathic pain behavior [25] .
Relationship of chemokines to diseaserelated chronic pain
Neuropathic pain is a topic of some concern for individuals with autoimmune or life-threatening diseases as the pain syndromes are difficult to treat and significantly detract from the quality of life. A prime example is the pain syndrome called distal symmetrical polyneuropathy (DSP), which affects as many as one-third of all HIVinfected individuals [47] . This painful sensory neuropathy frequently begins with paresthesias in the fingers and toes progressing over weeks to months, followed by the development of pain, often of a burning and lancinating nature, which can make walking very difficult. Measurements of pain hypersensitivity have demonstrated allodynia and hyperalgesia in HIV-1-infected individuals despite the absence of productive viral infection in the peripheral neurons. Subsequently, indirect effects of HIV-1 must lead to the development of this pain state (e.g. viral coat protein gp120 binding to the HIV-1 coreceptors CCR5 or CXCR4 present on neurons) [48] . Given these parameters, there are two ways in which HIV-1-induced DSP may occur: (1) viral protein shedding in the peripheral nervous system enables gp120 to produce painful neuropathy via glial/nonneuronal signaling in the DRG and/or spinal cord [49, 50] or (2) gp120 directly activates sensory neurons [9, 51] .
Complicating matters further, patients with AIDS who are treated by highly active, antiretroviral therapeutical (HAART) agents can also develop a painful sensory neuropathy. Intriguingly, the symptoms of this syndrome are clinically indistinguishable from those of HIVinduced DSP, including a burning sensation in the hands and feet and hypersensitivity to pain. In fact, these two syndromes are usually seen in association with one another, making diagnosis more difficult.
Recent studies in rats shed new light on the mechanisms of HAART-induced DSP [39 ] . These studies found that the HAART drug 2 0 ,3 0 -dideoxycytidine (ddC) produced neuropathic pain behavior, increased CXCR4 mRNA expression in the DRG and significantly increased SDF1/CXCL12-dependent neuronal activation. Moreover, ddC-induced rodent pain behavior could be attenuated using the highly specific CXCR4 receptor antagonist AMD3100 [39 ] .
Peripheral nervous system inflammatory demyelinating diseases such as Guillain-Barré syndrome and CharcotMarie-Tooth disease types 1 and 4, as well as the central nervous system disease multiple sclerosis, can also be accompanied by neuropathic pain [52] . Epidemiological studies [53] suggest that chronic pain syndromes afflict 50-80% of patients with multiple sclerosis and 70-90% of individuals with Guillain-Barré syndrome. Diseaserelated components that may be central to this neuropathic pain symptomology may include axon degeneration and the resulting Wallerian degeneration [54] and/ or the upregulation and chronic expression of chemokines and their cognate receptors [55] [56] [57] .
There is presently little direct evidence of chemokines contributing to neuropathic pain in acute and chronic inflammatory demyelinating disorders in humans. However, direct study of several rodent models of demyelinating diseases known to elicit neuropathic pain behavior (including late-developing peripheral axon demyelination in periaxin knockout mice [58] , chemically induced transient focal demyelination of the sciatic nerve in mice and rats [31 ,59] and the late, acute clinical phase of experimental autoimmune neuritis [60] ) may be instrumental in determining the possible role of chemokineinfluenced chronic pain. Moreover, recent studies [31 ] of rats and mice (Bhangoo and White, unpublished observations) subjected to transient focal demyelination of the sciatic nerve exhibit chronic upregulation of MCP-1/ CCL2 and interferon g producing protein-10 (IP-10/ CXCL10) and the chemokine receptors CCR2, CCR5, and CXCR4 in primary sensory neurons. These chemokines/receptors may effectively modulate the accompanying chronic pain behavior by modifying the manner in which these sensory neurons respond to peripheral stimuli.
Conclusion
Chemokines are responsible for specific recruitment of leukoctyes during inflammation and disease. Besides the well established role of chemokines in the immune system, a number of chemokines and their receptors directly or indirectly exert their activity on adult neurons and glial cells where they are involved in intercellular communication. Many chemokines exhibit de-novo expression in the nervous system following the induction of disease and nerve injury, and may play a distinct role in chronic pain syndromes. There is uncertainty about the exact mechanism by which chemokines act in these pain states, as the effect of chemokines could impact on neurons in either a direct or indirect manner. Nonetheless, the data suggest that strategies aimed at limiting the actions of chemokines may result in an important new direction of therapy.
